177 results about "Malarial parasite" patented technology

Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.

The invention discloses a set of loop-mediated isothermal amplification technology-based plasmodium genus and species nucleic acid screening method and belongs to the field of biological detection. The method is performed by loop-mediated isothermal amplification (LAMP) technology, specific positions of target genes are amplified by using an LAMP technology platform through specific primers of plasmodium genera and specificity primers of plasmodium species, the plasmodium genera are screened or detected at a molecular level under assistance of positive and negative quality control and an internal control detection system, and plasmodium species screening or detection is performed on four kinds of plasmodia, namely Plasmodiumfalciparum, Plasmodiummalariae, Plasmodiumovale and Plasmodiumvivax which can make humans infected with malaria in plasmodium genus organisms. The invention has the characteristics that: the method is simple, economic and rapid, and has high sensitivity, high specificity and wide application prospect.

This invention relates to recombinant viruses based on MVA, which comprise at least one nucleic acid coding for a Plasmodium falciparum MSP-1 protein, a fragment or mutein of it. Furthermore, methods for the production of the recombinant viruses, virus-containing vaccines and the use of the recombinant viruses for the prophylaxis and / or therapy of malaria are provided.

The present invention relates to a recombinant human antibody comprising an antibodysequence specific for the MSP-3 antigen of Plasmodium falciparum. In particular, the invention relates to a recombinant human antibody which is specific for the MSP-3194-257 antigen. The invention further relates to nucleic acid encoding such antibodies and to uses of these antibodies, in particular in the treatment or prophylaxis of malaria.

The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.

Camptothecin derivatives of camptothecin of formula (I) wherein the groups R1, R2 and R3 are as defined in the description are disclosed. The compounds of formula (I) are endowed with antitumor activity and show a good therapeutic index. Processes for the preparation of the compounds of formula (I) and their use in the preparation of medicaments useful in the treatment of tumors, viral infections and antiplasmodium falciparum are also disclosed.

Pharmaceutical compositions comprising compounds of the formula where R1, R2, and R3 are described here, have therapeutic utility in selectively inhibiting P. falciparum dihydroorotate dehydrogenase. Accordingly, such compositions have use in the treatment and prevention of malaria.

The invention discloses a dihydroartemisinin diploid derivative, and a medicine composition and application thereof. The derivative is artemisinin diploid, and is applied to a medicine for treating or preventing malaria caused by plasmodium, a medicine for treating autoimmune diseases such as lupus erythematosus, and an antitumor medicine; the medicine composition is prepared from the dihydroartemisinin diploid derivative and a pharmaceutically acceptable carrier.

The invention relates to a multi-epitope artificial antigen of plasmodium falciparum and an application thereof. The invention designs a polynucleotide with a sequence as shown in SEQ ID No:1 and a polypeptide with a sequence as shown in SEQ ID No:2, wherein the polynucleotide and the polypeptide are used as artificial antigens to prepare vaccines, and antibodies can be obtained from the antigens and are used to prepare immune preparations against plasmodium falciparum infections and kits for detecting malaria infections. Compared with anti plasmodium falciparum vaccines in the prior art, the multi-epitope artificial antigen of the invention has high immunogenicity and antigen recognition diversity, and the antibody of the invention has high inhibition efficiency on the in vitro growth of plasmodium falciparum.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites. The compounds of the invention unexpectedly provide a single-dose cure for malaria, as well as prophylactic activity against the same. The compounds are also active against schistosomiasis and cancer.

Camptothecin derivatives of camptothecin of formula (I)exhibit antitumor activity and show a good therapeutic index and are used in the treatment of tumors, viral infections and antiplasmodium falciparum.

The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.

This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and / or treatment of parasite infection (e.g., Plasmodium parasites) and / or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and / or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and / or salts thereof.

The present invention relates to a novel bioactive water fraction obtained from the leaves of an herb named Gomphostema niveum commonly found in North Eastern part of India, and which is useful for inhibiting the growth of malarial parasite Plasmodium falciparum. The present invention also relates to a method for the extraction of said bioactive fraction. The present invention also provides methods for treatment of malaria using such bioactive water fractions and use of such bioactive water fractions for the treatment of malaria.

This invention is in the field of recombinant Plasmodium falciparum polypeptides and relates to recombinant or synthetic antigen compositions which comprise p42 antigens, and more specifically to methods and compositions for the expression of Plasmodium falciparum polypeptides in transgenic plants.

The present invention relates to novel compounds that are inhibitors of wild type and mutant dihydrofolate reductase (DHFR) of Plasmodium falciparum, which are useful for the treatment of malaria. It also relates to processes of making and using such compounds. The antimalarial compounds of the present invention have low toxicity to a host infected with the malarial parasite, and are potent when administered in pharmaceutical compositions.

The present invention relates to an immunoassay and diagnostic reagent for malaria by using antigens of malarial Protozoa. More preferably, the present invention relates to an immunoassay and diagnostic reagent for malaria which detect malaria-specific antibodies in blood by using Merozoite Surface Protein of Plasmodium vivax. The immunoassay and diagnostic reagent detecting malaria-specific antibodies in blood according to the present invention have high specificity and sensitivity and are useful in diagnosing a type of malaria where latent period is long and number of Protozoa in blood if few. Also, the present invention relates to a preparation method of the surface protein of malarial Protozoa using yeast or E.Coli. Preferably, the present invention provides an expression vector comprising genes of Merozoite Surface Protein of Plasmodium Vivax and histidine residues, as well as transformants transformed with the expression vector. Also, the present invention provides a method for preparing Merozoite Surface Protein of malarial Protozoa by using the transformant. The surface protein Merozoite Surface Protein of malarial Protozoa prepared from yeast or E.Coli transformant according to the present invention has high sensitivity and specificity to antibody as well as high purity. Also, the surface protein prepared by the preparation method of the present invention has markedly low pseudo-positive signals, and is useful in diagnosing malaria.

The invention relates to a propionamides compound and a usage thereof. The inventor, by carrying out SPR experiment based on Biacore and making comprehensive use of CADD, modifies the structure of a propionamide derivative and obtains an N-substituted-2-substituted amino-3-(1H-indole-3-yl) propionamides compound (the structure thereof is indicated by formula I). The falcipain-2 activity inhibiting capability of the obtained compound is tested, and the result shows that the prepared N-substituted-2-substituted amino-3-(1H-indole-3-yl) propionamides compound has strong falcipain-2 activity inhibiting capability and can be used for preparing medicaments for treating malaria caused by plasmodium.

The invention relates to the gene exploitation and application field of the biomedicine high-tech, in particular to an artificial antigen amino acid sequence which is provided with a plurality of epipositions and can be identified by blood serum of falciparum malaria sufferers and a polynucleotide sequence coded with the amino acid sequence. The invention also relates to a vaccine containing the amino acid sequence or the polynucleotide sequence. The invention further also relates to the application of the artificial antigen used for preparing the immunity preparation against the falciparum malaria parasite.

A means and method for treating malaria, schistosomiasis, and cancer using a Spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

The invention discloses dihydroxy isoquinoline and a preparation method and application thereof from centipedes, and belongs to the field of medicine. The dihydroxy isoquinoline is 3,8-dihydroxy isoquinoline, is extracted from centipedes and can be used for treating malaria and solid tumors and killing bacteria. The malaria is plasmodium vivax, malaria plasmodium, plasmodium falciparum and plasmodium ovale parasitizing the human body. The bacteria are escherichia coli, staphylococcus aureus, pseudomonas aeruginosa, alpha / beta hemolytic streptococcus, streptococcus pneumoniae and haemophilus influenzae. The tumors are primary or secondary cancers and sarcomas deriving from the head and neck portion, brain, thyroid gland, pancreas, lungs, liver, esophagus, stomach, mammary gland, kidneys, gall bladder, colon or rectum, ovary, uterus, cervix uterus, prostate, bladder and testis of the human body. The dihydroxy isoquinoline has small toxic and side effects, and can be used for treatment and auxiliary treatment of various cancers.

Disclosed herein are diagnostic assays for identifying individuals that are protected against Plasmodium falciparum caused malaria. Such assays are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. The assays comprise the use of proteomes representing at least 50% of Pf, preferably coupled to a solid phase as a fixed array. The arrays are used to probe the sera of human subjects, particularly subjects of human clinical trials of whole parasite malaria vaccines as well as public health vaccination campaigns. Serum samples with antibody profiles most strongly reactive in multiplex to CSP and MSP5 demonstrate a sensitivity of from 92% to 100% and a specificity of from 84% to 89%.

The invention relates to a pernicious malarial parasite new gene, called msra-1, coding a malaria infected patiendt serum recognizing antigen-1 of P.f from pernicious malarial parasite. It also relates to the new gene-coded protein product, and the immunological usage of the new gene and the protein at the aspect of anti-pernicious malarial parasite.

The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.